OyaGen

OyaGen is a biotechnology company dedicated to developing novel drug therapies aimed at RNA and DNA editing enzymes. Committed to the discovery, development, and commercialization of innovative drug therapies, the company seeks to develop RNA and DNA editing enzymes specifically targeting HIV/AIDS. OyaGen has expanded its original business model to a broad scope, including the discovery of novel drug leads for various infectious diseases. Over the past decade, OyaGen has developed drug discovery approaches enabling it to explore vulnerabilities in HIV, Ebola virus, and coronaviruses. The company has patented and developed leading compounds that have the potential to serve as first-in-class therapies for treating HIV. These experimental therapies protect the human host defense system, composed of DNA editing enzymes, from degradation by the HIV Vif protein. This treatment allows the editing enzymes to attack and neutralize the ability of HIV-infected cells.